(Q48013156)

7 February 2018

title

Functional precision cancer medicine-moving beyond pure genomics. (English)

1 reference

7 February 2018

1 reference

Anthony Letai

1

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 September 2017

1 reference

7 February 2018

published in

Nature Medicine

1 reference

7 February 2018

volume

23

1 reference

7 February 2018

issue

9

1 reference

7 February 2018

page(s)

1028-1035

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1038/nm.4389

exact match

0 references

cites work

Precision oncology: a strategy we were not ready to deploy.

1 reference

Precision medicine for cancer with next-generation functional diagnostics

21 January 2018

1 reference

Precision oncology: origins, optimism, and potential

21 January 2018

1 reference

Limits to Personalized Cancer Medicine.

21 January 2018

1 reference

No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data

21 January 2018

1 reference

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

21 January 2018

1 reference

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

21 January 2018

1 reference

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

21 January 2018

1 reference

Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy

21 January 2018

1 reference

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

21 January 2018

1 reference

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

21 January 2018

1 reference

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice

21 January 2018

1 reference

Institutional implementation of clinical tumor profiling on an unselected cancer population

21 January 2018

1 reference

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

21 January 2018

1 reference

Characteristics of Exceptional or Super Responders to Cancer Drugs

21 January 2018

1 reference

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

21 January 2018

1 reference

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

21 January 2018

1 reference

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

21 January 2018

1 reference

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

21 January 2018

1 reference

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

21 January 2018

1 reference

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

21 January 2018

1 reference

Defining actionable mutations for oncology therapeutic development.

21 January 2018

1 reference

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

21 January 2018

1 reference

Prioritizing targets for precision cancer medicine

21 January 2018

1 reference

A decision support framework for genomically informed investigational cancer therapy

21 January 2018

1 reference

Targeted therapies for CLL: Practical issues with the changing treatment paradigm

21 January 2018

1 reference

Defining a Cancer Dependency Map.

21 January 2018

1 reference

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

21 January 2018

1 reference

Chemotherapy sensitivity and resistance assays: a systematic review

21 January 2018

1 reference

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

21 January 2018

1 reference

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

21 January 2018

1 reference

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

21 January 2018

1 reference

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

21 January 2018

1 reference

Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.

21 January 2018

1 reference

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

21 January 2018

1 reference

Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study

21 January 2018

1 reference

Patient-derived xenograft models: an emerging platform for translational cancer research

21 January 2018

1 reference

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

21 January 2018

1 reference

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

21 January 2018

1 reference

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

21 January 2018

1 reference

Mitochondria-Judges and Executioners of Cell Death Sentences

21 January 2018

1 reference

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

21 January 2018

1 reference

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

21 January 2018

1 reference

iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry.

21 January 2018

1 reference

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML

21 January 2018

1 reference

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

21 January 2018

1 reference

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

21 January 2018

1 reference

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.

21 January 2018

1 reference

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

21 January 2018

1 reference

High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays.

21 January 2018

1 reference

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.

21 January 2018

1 reference

An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

21 January 2018

1 reference

First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.

21 January 2018

1 reference

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.

21 January 2018

1 reference

A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo

21 January 2018

1 reference

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor

21 January 2018

1 reference

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

21 January 2018

1 reference

Perspective: The precision-oncology illusion

21 January 2018

1 reference

Translating cancer research into targeted therapeutics

21 January 2018

1 reference

Precision medicine: lessons learned from the SHIVA trial

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NM.4389

1 reference

7 February 2018

PubMed ID

28886003

1 reference

7 February 2018